Samuel Kareff, MD, MPH
@samuelkareffmd.bsky.social
MedOnc/Heme @BHCancerCare+CHO #BocaRaton #DelrayBeach
Former #MedEd Chiefs @HemOncMiami +
@gtown_medres
Tweets/likes ≠ medical advice | he/him | #LCSM | #GISM
Former #MedEd Chiefs @HemOncMiami +
@gtown_medres
Tweets/likes ≠ medical advice | he/him | #LCSM | #GISM
Reflecting on a data-packed
@iaslc.bsky.social #WCL25 with non-clinical panels on Narrowing Disparities in Effective Management of Lung Cancer on the Global Scale and the
@who.int
#IntegratedLungHealthResolution stand out most--time to bring these findings home!
@iaslc.bsky.social #WCL25 with non-clinical panels on Narrowing Disparities in Effective Management of Lung Cancer on the Global Scale and the
@who.int
#IntegratedLungHealthResolution stand out most--time to bring these findings home!
September 11, 2025 at 9:18 AM
Reflecting on a data-packed
@iaslc.bsky.social #WCL25 with non-clinical panels on Narrowing Disparities in Effective Management of Lung Cancer on the Global Scale and the
@who.int
#IntegratedLungHealthResolution stand out most--time to bring these findings home!
@iaslc.bsky.social #WCL25 with non-clinical panels on Narrowing Disparities in Effective Management of Lung Cancer on the Global Scale and the
@who.int
#IntegratedLungHealthResolution stand out most--time to bring these findings home!
Reposted by Samuel Kareff, MD, MPH
The MARIPOSA effect 🦋
‼️Awaited OS data for #Amivantamab + lazertinib vs osimertinib in 1L EGFRm advanced #lungcancer presented at #ELCC25
🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎉> 1 yr mOS advantage
🚫no crossover allowed, ⬆️intracranial activity
⬇️toxicity over time w prophylactic mgmt (skin)
#lcsm
‼️Awaited OS data for #Amivantamab + lazertinib vs osimertinib in 1L EGFRm advanced #lungcancer presented at #ELCC25
🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎉> 1 yr mOS advantage
🚫no crossover allowed, ⬆️intracranial activity
⬇️toxicity over time w prophylactic mgmt (skin)
#lcsm
March 27, 2025 at 2:25 AM
The MARIPOSA effect 🦋
‼️Awaited OS data for #Amivantamab + lazertinib vs osimertinib in 1L EGFRm advanced #lungcancer presented at #ELCC25
🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎉> 1 yr mOS advantage
🚫no crossover allowed, ⬆️intracranial activity
⬇️toxicity over time w prophylactic mgmt (skin)
#lcsm
‼️Awaited OS data for #Amivantamab + lazertinib vs osimertinib in 1L EGFRm advanced #lungcancer presented at #ELCC25
🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎉> 1 yr mOS advantage
🚫no crossover allowed, ⬆️intracranial activity
⬇️toxicity over time w prophylactic mgmt (skin)
#lcsm
Join us today at noon EST for free #PatientEducation to discuss all things new in the management of Colorectal Cancers @BHCancerCare @BaptistHealthSF @MiamiCancerInst
#CRCSM #PatientEducation
#CRCSM #PatientEducation
March 14, 2025 at 11:29 AM
Join us today at noon EST for free #PatientEducation to discuss all things new in the management of Colorectal Cancers @BHCancerCare @BaptistHealthSF @MiamiCancerInst
#CRCSM #PatientEducation
#CRCSM #PatientEducation
Reposted by Samuel Kareff, MD, MPH
3 points of progress vs pancreatic cancer!
1. Neoantigen vaccines
www.nature.com/articles/s41...
2. KRAS drugs
www.wsj.com/health/healt...
3. Early diagnosis www.science.org/doi/10.1126/...
1. Neoantigen vaccines
www.nature.com/articles/s41...
2. KRAS drugs
www.wsj.com/health/healt...
3. Early diagnosis www.science.org/doi/10.1126/...
March 1, 2025 at 3:26 PM
3 points of progress vs pancreatic cancer!
1. Neoantigen vaccines
www.nature.com/articles/s41...
2. KRAS drugs
www.wsj.com/health/healt...
3. Early diagnosis www.science.org/doi/10.1126/...
1. Neoantigen vaccines
www.nature.com/articles/s41...
2. KRAS drugs
www.wsj.com/health/healt...
3. Early diagnosis www.science.org/doi/10.1126/...
First lecture as faculty yesterday to the @FAUCollegeofMedicine + @WPBVAHCS Pulmonology team. 🫁 cancers are still a team sport in 2025 and beyond! @iaslc.bsky.social @ascocancer.bsky.social @FLASCO_ORG @BHCancerCare
January 3, 2025 at 4:22 PM
First lecture as faculty yesterday to the @FAUCollegeofMedicine + @WPBVAHCS Pulmonology team. 🫁 cancers are still a team sport in 2025 and beyond! @iaslc.bsky.social @ascocancer.bsky.social @FLASCO_ORG @BHCancerCare